KR20240033130A - Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여 - Google Patents
Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여 Download PDFInfo
- Publication number
- KR20240033130A KR20240033130A KR1020247006668A KR20247006668A KR20240033130A KR 20240033130 A KR20240033130 A KR 20240033130A KR 1020247006668 A KR1020247006668 A KR 1020247006668A KR 20247006668 A KR20247006668 A KR 20247006668A KR 20240033130 A KR20240033130 A KR 20240033130A
- Authority
- KR
- South Korea
- Prior art keywords
- drug
- patient
- methylphenidate
- skamp
- adhd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 19
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 title description 44
- 229960001344 methylphenidate Drugs 0.000 title description 43
- 238000000034 method Methods 0.000 claims description 20
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract description 37
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract description 36
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract description 34
- 239000000556 agonist Substances 0.000 abstract description 11
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 description 63
- 229940079593 drug Drugs 0.000 description 48
- 239000003814 drug Substances 0.000 description 48
- 230000003285 pharmacodynamic effect Effects 0.000 description 37
- 239000013583 drug formulation Substances 0.000 description 26
- 230000037396 body weight Effects 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 20
- 238000009472 formulation Methods 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- 238000000576 coating method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000009467 reduction Effects 0.000 description 15
- 238000005259 measurement Methods 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 239000011248 coating agent Substances 0.000 description 13
- 230000003111 delayed effect Effects 0.000 description 11
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 230000007423 decrease Effects 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000036470 plasma concentration Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 230000000857 drug effect Effects 0.000 description 7
- 238000013265 extended release Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000004088 simulation Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 239000012738 dissolution medium Substances 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000003657 Likelihood-ratio test Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000007476 Maximum Likelihood Methods 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000036626 alertness Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000013180 random effects model Methods 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- CETWSOHVEGTIBR-FORAGAHYSA-N (2s)-2,6-diamino-n-[(2s)-1-phenylpropan-2-yl]hexanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 CETWSOHVEGTIBR-FORAGAHYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000004093 Mitragyna parvifolia Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 229940047812 adderall Drugs 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940098357 daytrana Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229960000357 lisdexamfetamine dimesylate Drugs 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960001033 methylphenidate hydrochloride Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940099204 ritalin Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- General Physics & Mathematics (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662415884P | 2016-11-01 | 2016-11-01 | |
| US62/415,884 | 2016-11-01 | ||
| PCT/US2017/059256 WO2018085256A1 (en) | 2016-11-01 | 2017-10-31 | Effective dosing of a child for the treatment of adhd with methylphenidate |
| KR1020197015402A KR20190107655A (ko) | 2016-11-01 | 2017-10-31 | Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197015402A Division KR20190107655A (ko) | 2016-11-01 | 2017-10-31 | Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240033130A true KR20240033130A (ko) | 2024-03-12 |
Family
ID=62076554
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247006668A Pending KR20240033130A (ko) | 2016-11-01 | 2017-10-31 | Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여 |
| KR1020197015402A Ceased KR20190107655A (ko) | 2016-11-01 | 2017-10-31 | Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197015402A Ceased KR20190107655A (ko) | 2016-11-01 | 2017-10-31 | Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11166947B2 (https=) |
| EP (1) | EP3585439A4 (https=) |
| JP (1) | JP2020504763A (https=) |
| KR (2) | KR20240033130A (https=) |
| AU (1) | AU2017353921B2 (https=) |
| WO (1) | WO2018085256A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021195155A1 (en) * | 2020-03-23 | 2021-09-30 | Genentech, Inc. | Estimating pharmacokinetic parameters using deep learning |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01004381A (es) | 1998-11-02 | 2005-09-08 | Elan Corp Plc | Composicion de multiparticulado de liberacion modificada. |
| US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
| US6344215B1 (en) * | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
| EP2726066B1 (en) * | 2011-06-28 | 2021-03-31 | Neos Therapeutics, LP | Dosage forms of amphetamine for oral administration |
| CA2880456A1 (en) * | 2012-08-15 | 2014-02-20 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
| CA2951072A1 (en) | 2014-06-06 | 2015-12-10 | Rhodes Pharmaceuticals, L.P. | Methods for treating attention deficit hyperactivity disorder with methylphenidate |
-
2017
- 2017-10-31 JP JP2019544799A patent/JP2020504763A/ja active Pending
- 2017-10-31 WO PCT/US2017/059256 patent/WO2018085256A1/en not_active Ceased
- 2017-10-31 US US16/346,850 patent/US11166947B2/en active Active
- 2017-10-31 EP EP17868418.9A patent/EP3585439A4/en active Pending
- 2017-10-31 KR KR1020247006668A patent/KR20240033130A/ko active Pending
- 2017-10-31 KR KR1020197015402A patent/KR20190107655A/ko not_active Ceased
- 2017-10-31 AU AU2017353921A patent/AU2017353921B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190314356A1 (en) | 2019-10-17 |
| WO2018085256A1 (en) | 2018-05-11 |
| JP2020504763A (ja) | 2020-02-13 |
| AU2017353921A1 (en) | 2019-06-13 |
| EP3585439A4 (en) | 2020-07-22 |
| KR20190107655A (ko) | 2019-09-20 |
| EP3585439A1 (en) | 2020-01-01 |
| US11166947B2 (en) | 2021-11-09 |
| AU2017353921B2 (en) | 2023-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Psychomotor recovery following remimazolam-induced sedation and the effectiveness of flumazenil as an antidote | |
| Brown et al. | Pharmacokinetics of escalating doses of oral psilocybin in healthy adults | |
| Muehlan et al. | Accelerated development of the dual orexin receptor antagonist ACT‐541468: integration of a microtracer in a first‐in‐human study | |
| Brody et al. | Cigarette smoking saturates brain α4β2 nicotinic acetylcholine receptors | |
| Krekels et al. | From pediatric covariate model to semiphysiological function for maturation: part I–extrapolation of a covariate model from morphine to zidovudine | |
| Culbertson et al. | Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers | |
| Kimko et al. | Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis | |
| Bizikova et al. | Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs | |
| Caballero-Puntiverio et al. | Effects of amphetamine and methylphenidate on attentional performance and impulsivity in the mouse 5-Choice Serial Reaction Time Task | |
| Hestehave et al. | Small molecule targeting NaV1. 7 via inhibition of CRMP2-Ubc9 interaction reduces pain-related outcomes in a rodent osteoarthritic model | |
| Bakker et al. | Biperiden Challenge Model in Healthy Elderly as Proof‐of‐Pharmacology Tool: A Randomized, Placebo‐Controlled Trial | |
| Bruehl et al. | Stress-induced analgesia: an evaluation of effects on temporal summation of pain and the role of endogenous opioid mechanisms | |
| Faraone et al. | Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: machine learning post hoc analysis of a phase 3 clinical trial | |
| Moorthy et al. | Safety, tolerability and pharmacokinetics of 2‐pyridylacetic acid, a major metabolite of betahistine, in a phase 1 dose escalation study in subjects with ADHD | |
| Hsu et al. | The influence of light administration on interpersonal behavior and affect in people with mild to moderate seasonality | |
| Hawro et al. | Comparison of pruritus and sensory qualities induced by capsaicin, histamine and cowhage | |
| Stoops et al. | Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users | |
| Magliocca et al. | Nighttime safety of daridorexant: Evaluation of responsiveness to an external noise stimulus, postural stability, walking, and cognitive function | |
| Yau et al. | Mechanism‐based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients | |
| Zeng et al. | Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation | |
| Jacobs et al. | Psychedelic medicine: mechanisms, evidence, and translation to practice | |
| Wallgren et al. | Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer's Disease | |
| Cicali et al. | Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: physiologically‐based modeling as a candle in the dark | |
| KR20240033130A (ko) | Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여 | |
| Rajendram et al. | Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: A multi-centre, double-masked, factorial randomised controlled trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20240227 Application number text: 1020197015402 Filing date: 20190529 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20240328 Comment text: Request for Examination of Application |